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ABSTRACT
Atrial fibrillation (AF) is common in patients with chronic kidney disease (CKD), affecting 10–25% of patients requiring
dialysis. Compared with the general population, patients requiring dialysis are also at increased risk of stroke, the major
thromboembolic complication of AF. The evidence base for management strategies of AF specific to patients with advanced
CKD is limited and not informed by randomized controlled trials. These gaps in evidence encompass rate and rhythm
control strategies as well as a paucity of data informing which patients should receive anticoagulation. The European Renal
Association–European Dialysis and Transplant Association and European Heart Rhythm Association undertook a survey of
nephrologists and cardiologists exploring management strategies in patients with AF and CKD. We review the results of
this survey, highlighting the differences in clinical approaches from cardiologists and nephrologists to these conditions.
Closer collaboration between these specialties should lead to improved outcomes for patients with advanced CKD and AF.
Specific issues that will need to be addressed may include healthcare burden to patients, location of clinics compared with
dialysis sites and awareness of complications of treatments specific to CKD, such as calciphylaxis associated with vitamin K
antagonism.
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BACKGROUND
The prevalence of atrial fibrillation (AF) increases with declining
kidney function to the point where 10–25% of patients with
end-stage renal disease (ESRD) requiring dialysis or transplanta-
tion will have symptomatic AF [1–3]. AF and chronic kidney
disease (CKD) have several shared risk factors, including diabe-
tes, advancing age and prior ischaemic heart disease.
Inflammation may also have a contributory role in atrial struc-
tural remodelling and AF inducibility. Moreover, ESRD presents
specific scenarios that exacerbate the risk of AF, such as vari-
ability in serum potassium and other electrolytes throughout
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the dialysis cycle. Patients with ESRD have a high prevalence of
structural cardiac disease that may augment the propensity to
develop AF, such as left atrial enlargement, left ventricular hy-
pertrophy and associated cardiac filling disorders and myocar-
dial fibrosis, which may affect cardiac conduction [4–6].
The major thromboembolic complication of AF is stroke. In
patients without major renal dysfunction, anticoagulation with
vitamin K antagonists (VKAs) or non-vitamin K oral anticoagu-
lants (NOACs) has been shown to be an effective treatment to
reduce the risk of stroke in patients with AF, considered to be at
increased risk of stroke using a risk score such as CHA2DS2-
VASc [7]. The major complication of anticoagulation is bleeding,
and bleeding risk can be assessed prior to commencement of
anticoagulant therapy using bleeding risk scores such as the
HAS-BLED score [8].
Unfortunately, patients with advanced CKD, including dialy-
sis patients, have been excluded from randomized clinical trials
of anticoagulation for stroke prevention in AF [9, 10]. ESRD is a
risk factor for stroke, with a much higher incidence of stroke in
patients with ESRD compared with the general population, both
in patients with and without AF [1, 11]. Similarly, patients with
advanced CKD are at increased risk of bleeding compared with
the general population, even prior to commencing anticoagula-
tion and after commencing anticoagulation [12, 13].
Therefore the risk:benefit ratio for commencement of anti-
coagulation in patients with advanced CKD, including patients
requiring dialysis, is complex and not informed by randomized
controlled trials (RCTs). In addition to this, the optimal methods
for monitoring and adjusting VKA doses are far from being
established in advanced CKD, making the time within the thera-
peutic international normalized ratio range more unstable and
less predictable compared with patients without CKD. Warfarin
dosing algorithms are underused in nephrological practice.
These aspects may further foster either the bleeding or throm-
botic risk of advanced CKD patients.
Nevertheless, in the face of a high prevalence of AF and ele-
vated risk of stroke, clinicians are required to make therapeutic
decisions to mitigate stroke risk informed by a limited evidence
base. Recently the European Renal Association–European
Dialysis and Transplant Association (ERA-EDTA) and European
Heart Rhythm Association (EHRA) undertook a survey of both
nephrologists and cardiologists, exploring attitudes and thera-
peutic decision making in patients with AF and advanced CKD
[14]. The results highlight heterogeneous approaches to man-
agement in these patients, perhaps reflecting the gap in evi-
dence to inform clinical practice. It appears that although the
cardiac rhythm of AF is the same, cardiologists and nephrolo-
gists do appear to be literally singing different lyrics. We discuss
the survey and highlight the major areas of divergence of opin-
ion and what evidence is required to better inform future thera-
peutic decisions.
The EHRA and ERA-EDTA survey of attitudes of
physicians in the treatment of AF in patients with CKD
The EHRA and ERA-EDTA jointly conducted a physician-based
survey examining nephrologists and cardiologists approaches
to AF in patients with CKD [14]. In total, 306 physicians
responded to the survey, with approximately an even split be-
tween cardiologists and nephrologists, with 160 EHRA-affiliated
physicians (52.3%) and 146 respondents affiliated with ERA-
EDTA (47.7%). The respondents to the survey were primarily
based in university-based public hospitals; as expected, the ma-
jority of them responded from Europe. The main characteristics
of the respondents are summarized in Figure 1. More EHRA
respondents were fellows in training, while the majority of the
ERA-EDTA respondents had been in practice for >10 years.
While, as expected, >90% of ERA-EDTA participants had experi-
ence managing AF in patients requiring haemodialysis (HD), the
majority of EHRA respondents had extensive experience of AF
in CKD, with 73.8% having seen HD patients with AF.
The survey addressed a number of key issues in the manage-
ment of patients with advanced CKD and AF, including the need
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FIGURE 1: Main differences between cardiologists and nephrologists who answered the joint survey of the EHRA and ERA/EDTA [14]. Data are expressed as the percent-
age of respondents of both associations. ND-CKD, non-dialysis CKD.
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measurement of renal function in patients with AF, screening
for AF, stroke prevention strategies, use of specific anticoagula-
tion drugs and strategies for rate and rhythm control in patients
with AF and CKD. Before delving into the results of this survey,
it is worth remembering that there are fairly limited data to sup-
port any particular management strategy for AF in advanced
CKD. A Kidney Disease: Improving Global Outcomes (KDIGO)
Controversies Conference in 2016 highlighted that patients with
CKD have frequently being excluded from clinical trials of anti-
coagulation and arrhythmia strategies and that there are major
gaps in the evidence used to inform the best management of
these patients [15].
Clinical management of patients with CKD and AF
There are some divergences in practices and areas where gen-
eral care might be improved. Less than 10% of respondents to
the EHRA/ERA-EDTA survey used multidisciplinary teams for
managing patients with CKD and AF [14]. Only 12.5% of cardiolo-
gists were of the opinion that there was no collaboration be-
tween the cardiology and nephrology team, while 37.9% of
nephrologists suggested that there was a lack of collaboration.
There are multiple reasons for this, but it typically reflects the
experience that nephrologists caring for patients requiring dial-
ysis often are required to function autonomously and undertake
several non-nephrological aspects of patient management sim-
ply to minimize the healthcare burden. The cardiologists may
simply be unaware of dialysis patients with AF who are either
not referred to cardiology or patients may prefer to have man-
agement undertaken by their renal team, with whom they are
familiar.
Some areas of care are fairly uncontroversial. Similar propor-
tions of clinicians would screen for AF and a single
electrocardiogram would be the preferred means of screening
for >80% of both cardiologists and nephrologists. However, it
should be noted that previously undocumented AF is commonly
detected in up to 41% of dialysis patients in studies using im-
plantable loop recorders [16, 17].
Whether and how to offer anticoagulation?
One of the major tenets of management of AF is the use of
thromboprophylaxis with oral anticoagulation to reduce the
risk of stroke. The most commonly used risk score for predicting
stroke risk is the CHA2DS2-VASc, with anticoagulation typically
offered to patients with CHA2DS2-VASc scores 2 in females
and 1 in males [7]. The risk of bleeding typically estimated
with the HAS-BLED score may further inform which patients
may be less likely to benefit from anticoagulation due to excess
risk of bleeding [8]. Despite patients with ESRD being at a con-
siderably higher risk (3–6 times higher) of stroke than patients
with normal kidney function [11], there are no data to support
the use of risk scores for offering anticoagulation in ESRD.
Furthermore, as kidney function is a component of the HAS-
BLED score, its utility in advanced CKD is likely to be con-
founded. In the EHRA/EDTA-ERA survey, a number of scenarios
based on CHA2DS2-VASc and HAS-BLED risk scores were pre-
sented in the survey to test the opinion of cardiologists and
nephrologists on when to offer anticoagulation. Both specialties
seemed to weight shared decision making with patients as im-
portant, but cardiologists seemed much more enthusiastic to
use CHA2DS2-VASc to guide decision making than nephrologists
when considering when to offer anticoagulation.
This highlights that familiarity with a risk score or equation
may be a greater driver than clinical appropriateness for selec-
tion of a methodology used for treatment decisions. While car-
diologists expressed enthusiasm for using CHA2DS2-VASc in
patients with advanced CKD with limited data to support this
approach, nephrologists preferred to use the Chronic Kidney
Disease Epidemiology Collaboration equation to assess renal
function for informing anticoagulant dosing. This is despite the
current European Medicines Agency licensing recommenda-
tions that NOACs are prescribed by Cockcroft–Gault creatinine
clearance rather than estimated glomerular filtration rate
(eGFR) [15].
Although rare, the association of VKA with calciphylaxis is
an additional concern when prescribing these agents in patients
requiring dialysis, particularly in patients with other risk factors
for calciphylaxis, such as obesity, severe CKD–mineral bone dis-
order (CKD-MBD) or diabetes [18]. Many cardiologists may not
be aware of the association between VKA and calciphylaxis, and
even if they are aware of this condition, they are unlikely to be
the physician who makes the diagnosis or provides inpatient
care for this condition. Even though it is rare, the severe pain,
secondary infection and poor survival associated with calciphy-
laxis are likely to further temper nephrologists’ enthusiasm for
prescribing VKA to patients requiring dialysis.
Do nephrologists consider rate or rhythm control in AF?
It appears that nephrologists are more comfortable with aiming
for rate control versus rhythm control (where the goal is rever-
sion to sinus rhythm) in patients with advanced CKD. This is
possibly due in part to the experience nephrologists have in
managing b-blockers as antihypertensive drugs. In contrast,
cardiologists seem more enthusiastic to offer therapies that
might restore patients to sinus rhythm either using catheter ab-
lation techniques or with antiarrhythmic drugs that would be
considered more specialized, such as propafenone, dronedar-
one or flecanide. Some of these preferences are likely to be
influenced by familiarity with procedures or drugs, but they
may also reflect access to follow-up monitoring, which would
be required to assess both efficacy and safety. The evidence
base is unclear, as there are limited or no data from RCTs to in-
form practice with these in patients requiring dialysis.
Therefore, despite patients with ESRD having a high prevalence
of AF and being at risk of paroxysmal AF due to fluid and elec-
trolyte shifts, it is possible that some patients with ESRD do not
access antiarrhythmic therapies with some clinical benefit. This
may be due to a combination of limited clinical data to support
their use combined with the unfamiliarity of nephrologists with
some specialized antiarrhythmic strategies. As an example, de-
spite the higher haemorrhagic risk of HD patients when receiv-
ing oral anticoagulation, catheter ablation is probably
underutilized.(RCTs)
Evidence base for therapeutic decisions for patients with
ESRD and AF
There is a high prevalence of AF and increased risk of stroke in
ESRD. There are limited data from appropriately conducted
RCTs of anticoagulation strategies in AF in ESRD to inform prac-
tice. Observational data from dialysis patients with AF in the
USA, where apixaban, dabigatran and rivaroxaban are licensed
in patients requiring dialysis, demonstrate no difference in risk
of stroke/systemic embolism between apixaban and warfarin
fhazard ratio [HR] 0.88 [95% confidence interval (CI) 0.69–1.12]g,
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but apixaban has been associated with a significantly lower risk
of major bleeding [HR 0.72 (95% CI 0.59–0.87)] [19]. A recent
meta-analysis examining randomized trials of anticoagulation
in patients with CKD and AF demonstrated that, compared with
VKAs, NOACs reduced the risk of stroke or systemic embolism
[risk ratio (RR) 0.79 (95% CI 0.66–0.93)] and haemorrhagic stroke
[RR 0.48 (95% CI 0.30–0.76)]. However, none of these 11 trials in-
cluded patients with ESRD [20]. The major trials of NOACs,
such as ARISTOLTE and ROCKET-AF, excluded patients with
a creatinine clearance <25 mL/min and 30 mL/min, respec-
tively [9, 10]. The RENal Haemodialysis Patients ALlocated
Apixaban Versus Warfarin in AF trial (ClinicalTrials.gov:
NCT02942407) has completed but not yet reported and AXADIA
is ongoing (ClinicalTrials.gov: NCT02933697). Both trials com-
pare apixaban with VKAs in participants with AF requiring HD.
Another ongoing trial [AVKDIAL (ClinicalTrials.gov:
NCT02886962)] is comparing VKAs with no oral anticoagulation
in patients with ESRD and AF. While one hopes that these tri-
als will help inform anticoagulation strategies for patients
with AF requiring dialysis, it is unlikely that these trials will be
of sufficient size to demonstrate both definitive efficacy and
safety benefits to conclusively inform clinical practice.
Furthermore, there remains a lack of high-quality data to in-
form the use of anticoagulation in patients not requiring dialy-
sis but with creatinine clearance <25 mL/min.
What are the potential opportunities to improve care?
The EHRA/EDTA-ERA survey highlighted that cardiologists and
nephrologists may have different approaches, but both groups
of clinicians are applying treatment strategies with the clear
goals of optimizing outcomes in patients with AF and advanced
CKD by reducing stroke risk and maintaining appropriate car-
diac rate and rhythm by applying the existing evidence base,
which is limited, to the individual patient. It is highly likely that
there are mutual learning opportunities to further tailor care.
Until recently, the obvious ways to allow both specialties to fur-
ther educate the other would be with a multidisciplinary meet-
ing, combined clinics and continuing medical education
meetings between both cardiology and nephrology. However,
amidst the current coronavirus disease 2019 pandemic, we are
learning new ways of practising medicine and interacting with
our patients while reducing unnecessary contacts. This may
permit more efficacious use of time and allow telemedicine
clinics whereby patients will have joint consultations with sev-
eral clinicians without the need for the clinicians and patients
to be in the same place. This should permit true shared decision
making, as the patient with ESRD may benefit from specialist
input from cardiology while guided by their nephrologist
around what impact anticoagulation or antiarrhythmics might
have on dialysis or transplant listing. The spectacular upscaling
of educational webinars during the pandemic will lend itself to
multispecialty education, without the need to commit to at-
tending a conference outside one’s main specialty.
Meanwhile, it is important that we continue to generate bet-
ter quality data to inform treatment strategies. This should in-
clude larger-scale registry data from patients with ESRD and AF
that includes antiarrhythmic therapy, anticoagulation data and
time in the therapeutic range in patients on VKA. More large-
scale RCTs of antithrombotic strategies are required to address
both stroke and bleeding risk in patients with ESRD and ad-
vanced non-dialysis-dependent CKD. Additionally, it is vital
that patients with advanced CKD and AF, who are at an elevated
risk for both stroke and bleeding, are included in future RCTs of
novel agents to reduce risk of thromboembolic stroke such as
factor XI and XII inhibition [21]. Taken together, when it comes
to the rhythm of AF, a more coordinated approach between ne-
phrology and cardiology may lead to a more harmonious out-
come for patients with advanced CKD.
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